01 Aug 2024 — Patients with tobacco use disorder experience a reduced desire to smoke when treated with semaglutide — a glucagon-like peptide receptor agonist (GLP-1RA) medication for type 2 diabetes and obesity — finds a new study conducted at the Case Western Reserve School of Medicine, US.

Leave a Reply

Your email address will not be published. Required fields are marked *

0
    0
    Your Cart
    Your cart is emptyReturn to Shop